Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

NCT06476119 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT06476119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06476119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes
Lead sponsor
The Netherlands Cancer Institute
Phase
Observational
Overall status
Recruiting
Start date
April 15, 2025
Completion date
September 15, 2034
Enrollment
490 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage i, triple negative breast cancer (tnbc)